Wedbush Reaffirms “Outperform” Rating for iTeos Therapeutics (NASDAQ:ITOS)
iTeos Therapeutics (NASDAQ:ITOS – Get Free Report)‘s stock had its “outperform” rating restated by investment analysts at Wedbush in a research report issued on Wednesday,RTT News reports. They currently have a $25.00 price objective on the stock. Wedbush’s target price points to a potential upside of 252.61% from the stock’s previous close. ITOS has been […]
iTeos Therapeutics (NASDAQ:ITOS – Get Free Report)‘s stock had its “outperform” rating restated by investment analysts at Wedbush in a research report issued on Wednesday,RTT News reports. They currently have a $25.00 price objective on the stock. Wedbush’s target price points to a potential upside of 252.61% from the stock’s previous close. ITOS has been […]
